First patients enter TARGET study, recently initiated by Cerenis Therapeutics to evaluate HDL nanoparticles in patients with esophageal cancer
Toulouse, FRANCE, Lakeland, UNITED STATES, November 22, 2017, 8.00 am CET – Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible) an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases, today announces further evolution of its use of HDL with the enrollment of the first patients in the TARGET study, recently initiated to evaluate HDL nanoparticles in patients with esophageal cancer.
About Cerenis Therapeutics
CERENIS Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative lipid metabolism therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess lipids is removed from arteries and is transported to the liver for elimination from the body.
CERENIS is developing a portfolio of lipid metabolism therapies, including HDL mimetics for patients with genetic HDL deficiency, as well as drugs which increase HDL for patients with a low number of HDL particles to treat atherosclerosis and associated metabolic diseases including Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH). CERENIS is well positioned to become one of the leaders in the HDL therapeutic market, with a broad portfolio of programs in development.
Source: Cerenis Theraputics